Sharing-our-perspective-page-header2



Sharing perspectives leads to greater understanding and fuels innovation. The ​Optum Insights ​blog is where we share our perspective and challenge preconceptions to clear a new path forward


  • Pfizer defers July 2018 price increases

    by
    • Optum Workers' Comp
    | Aug 16, 2018
    Tag Icon
    Diabetes, Pain Management, Workers' Compensation
    Pfizer announced that their July 1 medication price increases were rolled back due to market pressures. The intended price increases are not permanently suspended and Pfizer has stated that they have only been deferred until the end of the year.


  • Missouri enacts opioid prescribing limits

    by
    • Optum
    | Aug 09, 2018
    Tag Icon
    Workers' Compensation, Pain Management, Opioids, Government Affairs
    The Missouri Legislature, in the waning hours of its session, passed legislation containing numerous changes to existing laws governing medical and pharmacy practices. One tucked away segment of the bill imposes prescribing restrictions for initial prescriptions of opioids to treat acute pain.


  • Tennessee enacts enhanced opioid prescribing controls

    by
    • Optum Workers' Comp
    | Jun 01, 2018
    Tag Icon
    Opioids
    House Bill 1831 was recently signed by Tennessee’s Governor, which enacts prescribing restrictions on opioid analgesics; sets dose caps on morphine milligram equivalent (MME); and defines enhanced prescription drug monitoring program (PDMP) requirements. Effective July 1, 2018, the bill bases prescribing restrictions on various treatment timeframes and requires the prescriber to properly examine, justify and document the need for additional opioid treatment.


  • FDA approves first-in-class medication to prevent migraine

    by
    • Optum Workers' Comp
    | May 22, 2018
    Tag Icon
    Pain Management, FDA, Migraine
    The U.S. Food and Drug Administration (FDA) approved the first medication in a new class to prevent chronic migraine in adults. Aimovig™ (erenumab-aooe) will be marketed by Amgen Inc. as a self-administered, once monthly, subcutaneous (under the skin) injection.




Do you have a question for our
Government Affairs team?






Subscribe

Stay informed by signing up to receive our latest update. *Denotes a required field